Lonza Group AG (LONN.SW)
Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
At close: 05:30PM CEST
| Previous Close | 527.40 |
| Open | 528.40 |
| Bid | 529.00 x 0 |
| Ask | 529.20 x 0 |
| Day's Range | 524.80 - 532.40 |
| 52 Week Range | 308.60 - 599.40 |
| Volume | |
| Avg. Volume | 204,290 |
| Market Cap | 38.164B |
| Beta (5Y Monthly) | 0.64 |
| PE Ratio (TTM) | 59.73 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 4.00 (0.76%) |
| Ex-Dividend Date | May 13, 2024 |
| 1y Target Est | N/A |
- PR Newswire
NeuroSense Announces First Quarter 2024 Business Update
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases, today provides a business update.
- Business Wire
Vertex and Lonza to Build Dedicated Manufacturing Facility for Type 1 Diabetes (T1D) Cell Therapies
BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.
© 2024 Yahoo. All rights reserved.